CEA N-domain Segmentation for Anti-tumor Vaccine Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor vaccines targeting carcinoembryonic antigen (CEA) face limitations due to low immunogenicity and the presence of immunosuppressive regulatory T cells, which compromise their efficacy in blocking CEA-dependent adhesion events and metastasis.
Innovation Solution
Administration of the N-domain of CEA, either in its wild-type or deglycosylated mutant form, combined with an adjuvant such as poly I:C, to overcome immunological tolerance and induce an immune response capable of interfering with tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CEA-based vaccines are administered, then the immune system is stimulated to respond against CEA, but the low immunogenicity and presence of immunosuppressive regulatory T cells compromise the efficacy in blocking CEA-dependent adhesion events and metastasis
Solution Approach 1:
The patent divides the full-length CEA molecule into separate functional domains (N-domain, A3B3 domain) and uses them as distinct vaccine components. This segmentation allows targeted immunization against specific functional regions involved in adhesion and metastasis, overcoming the limitations of whole-molecule vaccination by focusing the immune response on critical epitopes while avoiding immunosuppressive effects.
Solution Approach 2:
The patent applies local quality by targeting specific domains (N-domain and A3B3 domain) that have distinct functional roles in CEA-mediated adhesion and metastasis. Each domain elicits specialized immune responses tailored to block specific pathological functions, rather than inducing a generalized response against the entire CEA molecule.
2Adaptability or versatility
If full-length CEA molecule is used as vaccine, then comprehensive immune coverage is achieved, but the immunogenicity remains low and efficacy is compromised
Solution Approach 1:
The vaccine strategy segments the full-length CEA into functionally distinct domains (N-domain, A3B3 domain) that can be administered separately or in combination. This segmentation enhances immunogenicity by presenting smaller, more immunoreactive epitopes to the immune system, while maintaining comprehensive coverage of critical functional regions involved in adhesion and metastasis.
Solution Approach 2:
The patent changes the molecular parameters of the vaccine antigen by using truncated domain versions instead of the full-length CEA molecule. This parameter change increases immunogenicity by reducing molecular complexity and presenting more accessible epitopes, while maintaining or improving adaptability through targeted domain selection.
3Reliability
If conventional vaccines are used, then general immune stimulation occurs, but they fail to effectively block CEA-specific cellular adhesion events and metastasis
Solution Approach 1:
The patent segments the CEA molecule into functionally distinct domains (N-domain for adhesion events, A3B3 domain for metastasis) and develops targeted vaccine formulations for each. This segmentation enables reliable blocking of specific CEA-mediated pathological processes while maintaining relatively simple vaccine formulations compared to attempting to address all CEA functions simultaneously.
Solution Approach 2:
The vaccine strategy applies local quality by matching specific CEA domains to their functional roles: N-domain vaccine components target adhesion events, while A3B3 domain components target metastasis. This functional matching achieves reliable blocking of specific pathological processes without requiring complex multi-component formulations.
Data Source
AI summary
The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.